Abstract
The urinary excretion of 2,3-dinor-TxB 2 and 2,3-dinor-6-keto-PGF 1a (the major urinary metabolites of thromboxane B 2 and prostacyclin) was measured in ten patients with confirmed deep vein thrombosis, using specific methods based on gas chromatography — mass spectrometry with deuterium-labelled internal standards. Measurements of these major urinary metabolites makes it possible to monitor the in vivo formation of thromboxane A 2 and prostacyclin. The results demonstrate an abnormally high and very variable excretion of 2,3-dinor-TxB 2 and 2,3-dinor-6-keto-PGF in patients with deep vein thrombosis. This indicate that both thromboxane A 2 and prostacyclin are involved in the course of events associated with this disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
